Direct injection into the circulatory system. Re-exposure if there are known or suspected antibodies to bovine thrombin and/or factor V. Treatment of severe or brisk arterial bleeding. Thrombin ...

Direct inhibition of thrombin may offer similar anticoagulant properties but also impact the underlying disease process. As we continue to gain experience and develop new DTIs, a new balance may ...

but thrombin can be produced rapidly at the site of an injury. Production begins when tissue factor in the extrinsic coagulation pathway is exposed in a blood vessel. Tissue factor then binds ...

Thrombin is generally thought to be the activating ... as well as phospholipids (platelet factor 3) essential for intrinsic prothrombin conversion are liberated. Viscous metamorphosis, furthermore ...

thrombin and factor Xa (FXa). The recent approval of dabigatran etexilate for the prevention of venous thromboembolic events in patients who have undergone total hip- or knee-replacement surgery ...

Concizumab is a tissue factor pathway inhibitor antagonist that enhances factor Xa production during the initiation phase of coagulation. This production improves thrombin generation and clot ...